Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) belong to a group of mammalian immunoglobulin-related glycoproteins. The CEACAM family of proteins has been implicated in intracellular-signalingmediated effects that govern the growth and differentiation of normal and cancer cells.
INTRODUCTION
The carcinoembryonic antigen (CEA) family consists of two subfamilies, the CEACAM subgroup and the pregnancy specific glycoprotein (PSG) subgroup [1, 2] . Recent studies have shown that CEACAMs are members of the immunoglobulin superfamily, and that they are composed of an N-terminal domain (N) and six very homologous immunoglobulin constant region-like domains (A1, B1, A2, B2, A3 and B3) [3, 4] . The CEACAMs in the human being consist of 18 genes and 11 pseudogenes on chromosome 19q13.2.
CEACAMs are now recognized as being important not only as tumor markers but also as cell adhesion molecules [5, 6] . Furthermore CEACAMs are considered to be capable of transmitting the signals that result in a variety of effects depending on the tissue, including tumor suppression, tumor promotion, angiogenesis, neutrophil activation, lymphocyte activation and the cell cycle regulation [1] .
CEACAMs expression has been reported not only in normal and malignant mucosa of the gastrointestinal tract, *Address correspondence to this author at the 1-1-1 Honjo, Kumamoto 860-8556, Kumamoto, Japan; Tel: +81-96-373-5233; Fax: +81-96-373-5235; E-mail: ihn-der@kumamoto-u.ac.jp but also in some inflammatory diseases [3] and epithelial neoplasms [7] of the skin, gall bladder and extrahepatic biliary tract [8] . CEACAMs are also expressed in follicular keratinocytes [3, 9] and sweat gland apparatus [10, 11] in normal skin.
Concerning the psoriatic skin, CEACAM1 has been reported to be expressed in outer epidermal cell layers of the psoriatic skin [12] . Over expression of CEA was also demonstrated immunohistochemically [3, 13] . However, it remains unclear whether other CEACAMs are expressed in psoriatic skin.
In the present study, we aimed to evaluate the expression of CEACAMs by immunoblotting as well as immunohistochemical staining analysis. In the present study, we also developed an antigen retrieval method suitable for in situ CEACAMs expression in formalin-fixed materials.
MATERIAL AND METHODS

Materials
Totally 37 tissue samples of psoriasis vulgaris (28 formalin-fixed and 9 frozen specimens) were obtained from 28 patients who received biopsy in the Department of Dermatology and Plastic Surgery at Kumamoto University Hospital. Written informed consent to participate in the study was obtained from all the patients, which was approved by the institutional review board.
For histological and immunohistochemical analyses, 28 specimens were fixed in 10% formalin and embedded in paraffin. Nine of 28 specimens were divided into two pieces, one of which was frozen in liquid nitrogen and kept at -80°C for further analysis.
Antibodies Used
Three mouse monoclonal antibodies (F34-187, F33-104 and F106-88; developed by Kuroki et al.) and one rabbit polyclonal antibody raised against human CEACAMs (DakoPoAb) were used as primary antibodies. Epitope mapping analysis, using CEA and related antigens and various CEA and related recombinant proteins, has revealed the specificity of the monoclonal antibodies used here [14, 15] .
F34-187, which recognizes an epitope on domain N of CEA, reacts with CEA, CEACAM1 and CEACAM6 [14, 15] . F33-104, which recognizes an epitope on the B3 domain of CEA, seems to be specific for CEA [14, 15] . F106-88 reacts only with CEACAM6 [14, 15] . Dako-PoAb reacts with CEA and other CEACAM members.
A well-characterized PoAb against involucrin (Paesel), MoAbs against PCNA (Dako), Ki-67 (MIB-1, SANTA CRUZ BIOTECHNOLOGY, INC.) andCK16 (Novocastra) were also used as proliferation and/or differentiation markers to investigate the histological localization of the CEACAMs in comparison with the molecules.
Immunoblotting Analysis
Four frozen samples of psoriasis vulgaris and 3 of normal skin were used for immunoblotting analysis. The samples were frozen in liquid nitrogen and kept at -80°C. One frozen sample of rectal carcinoma was also used for positive control and human fibroblasts cultured in modified Eagle's medium supplemented with 10% fetal calf serum (FCS) and 50 g/ml amphotericin for negative control.
The specimens were homogenized and added phosphatidylinositol-specific phospholipase C (PI-PLC; Sigma) to cleave off the GPI-anchored proteins, such as CEA and CEACAM6, from the extracellular membrane. Then 20 l of the supernatant of the sample were exposed to 7.5% SDSpolyacrylamide gel electrophoresis before transferring to a nitrocellulose membrane. Blocking was achieved by incubating the membrane in 3% skimmed milk/Tris buffered saline with 0.2% Twin-20 (TBST) overnight at 4°C.
Dako-PoAb was applied at the dilution of 1:1000 and incubated overnight at 4°C, after which the membrane was incubated with goat anti-rabbit IgG-HRP for 60 min. Likewise, F33-104 (specific for CEA) and F106-88 (specific for CEACAM6) were applied at the dilution of 1:1000 and incubated overnight at 4°C, after which the membranes were incubated with goat anti-mouse IgG-HRP for 60 min. Membranes were washed with TBST and signals detected using the enhanced chemiluminescence system (Amersham Biosciences). -actin was used as a loading control.
Immunohistochemical Staining Analysis
Immunohistochemical staining for the expression of CEACAMs and the proliferation/differentiation markers was performed with Vectastain ABC kit (Vector Laboratories) on serial sections of frozen and/or formalin-fixed specimens.
In regard to the frozen material, 4 m cryostat sections were air-dried and fixed in acetone at 4°C for 10 min, whereas in regard to formalin-fixed material, after the sections were deparaffinized and rehydrated, antigen retrieval of CEACAMs was achieved by microwave treatment for 10 min in EDTA (1mmol/l, pH6.0), followed by cooling at room temperature for 60 min. After being washed in phosphate-buffered saline (PBS), the sections were treated with 3% hydrogen peroxide solution to reduce endogenous peroxidase activity. Those slides were incubated with the respective primary antibodies at 4°C overnight, washed in phosphate-buffered saline, treated with biotinylated anti-mouse (for MoAbs) or anti-rabbit (for Dako-PoAb) IgG (Vector Laboratories) for 30 min at room temperature, and rewashed. After 60 min of incubation with the avidin-biotin peroxidase complex (ABC, Vector Laboratories), the sections were washed in phosphate-buffered saline, developed in 0.05% diaminobenzidine diluted in phosphate-buffered saline with 0.01% hydrogen peroxide, dehydrated, and mounted. 11C2A4 (hybridoma protein; for F34-187, F33-104 and F106-88), normal mouse (Cappel Division, Organon Teknika Co.; for MoAbs), or rabbit serum (Cappel Division, Organon Teknika Co.; for PoAbs) were used as the negative controls. For positive controls, we examined normal eccrine glands and ducts in each section.
Double Immunoenzymatic Staining Analysis
Since the expression of CEACAMs was restricted to the upper epidermal cell layers, we performed the double immunoenzymatic staining analysis to compare the expression of the CEACAMs with that of involucrin, a well-characterized differentiation marker for the epidermal keratinocytes.
In brief, the sequential immunostaining procedure was carried out by first performing immunoperoxidase staining against F34-187, the monoclonal antibody attaining the clearest staining in our protocol, using the ABC method with a Vectastain ABC Kit (Vector Laboratories), and then the immunoalkaline phosphatase-antialkaline phosphatase (APAAP) method against involucrin (PoAb) was conducted with an APAAP Kit (Zymed Laboratories.). The sections were stained for peroxidase with diaminobenzidine and then stained with second primary antibody. As substrate solution for the alkaline phosphatase reaction, naphthol-AS-phosphatase (Sigma) and Fast Blue BB (Sigma) were dissolved in dimethylformamide and diluted with 0.1 mol/l Tris buffer, pH 8.2. To inhibit endogenous alkaline phosphatase activity, the incubation medium was supplemented with 0.25 mmol/l levamisole (Sigma).
RESULTS
Immunoblotting Analysis
Immunoblotting analysis revealed that the expression of both CEA and CEACAM6was up-regulated in psoriatic skin compared to normal skin, in which CEACAM6 expression was detected, but not CEA (Fig. 1) . Fig. (1) . Immunoblotting analysis of CEA and CEACAM6 expression in dermal fibroblasts, psoriasis skin, normal skin and rectal carcinoma. With F33-106 (specific for CEA), positive signal was seen only in psoriatic skin, whereas positive signal was seen in both psoriasis and normal skin with F106-88 (specific for CEACAM6), with much stronger signal in psoriatic skin than in normal skin. The -actin was used as a loading control.
Immunohistochemical Staining Analysis
Using a Dako-PoAb against CEACAMs, the histological distribution of all the CEACAM-expressing cells was visible in the psoriatic skin. The expression was obtained in the epidermal keratinocytes only in the upper epidermal cell layers, while no expression was seen in the basal and lower prickle cell layers and in perilesional normal skin (Fig. 2) . Positive signal was also seen on neutrophils in Munro's microabscess and some dermal and epidermal inflammatory infiltrating cells; the infiltration of the CEACAM-expressing inflammatory cells was restricted to the dermis just beneath the epidermis expressing the CEACAM, and was the denser infiltration of the CEACAM-expressing inflammatory cells seen in the dermis where the stronger expression of the CEACAM was seen in the overlying epidermis (Fig. 2) . Eccrine sweat glands and ducts were also positive for the antibody.
Heamatoxylin and eosin stain shows hyperkeratosis, parakeratosis, acanthosis and Munro's microabcess (Fig 3a) . In higher magnification, both membranous and cytoplasmic expression of the CEACAMs was seen in the epidermal keratinocytes (Fig. 3b) . Similar expression pattern was also seen with the F34-187 and F33-104 (Fig. 3c) in the epidermal keratinocytes, suggesting that CEA was expressed in the psoriatic keratinocytes and this was confirmed by the result of immunoblotting analysis. Neither neutrophils in Munro's microabscess nor inflammatory infiltrating cells showed positive signals with the F33-104, suggesting that CEA was not expressed in these cells (Fig. 3c) .
Using F106-88 (specific for CEACAM6), negative (Fig.  3d) to weak (Fig. 4) signal was obtained in the epidermal keratinocytes, depending on the samples studied, in contrast to that strong expression was seen by immunoblotting analysis using the same antibody as mentioned above. Neutophils in Munro's microabscess and inflammatory infiltrating cells were positive for F106-88, suggesting that CEACAM6 was expressed in the cells. Up-regulated expression of PCNA, Ki-67, CK16 and involucrin was also shown in the epidermal keratinocytes of the psoriatic skin: PCNA and Ki-67 were expressed in the keratinocytes of basal and lower prickle cell layers, while CK16 and involucrin were expressed in middle to upper epidermal cell layers (Fig. 5) .
The expression of the CEACAM was restricted to more de-differentiated. This finding was well demonstrated by double immunoenzymatic staining analysis (Fig. 6) .
DISCUSSION
Using a panel of antibodies that recognize different epitopes of CEACAMs, we clearly demonstrated that CEA and CEACAM6 were overexpressed in inflamed psoriasis skin. The expression was detected in membrane and cytoplasm of the epidermal keratinocytes whose distribution was restricted to the upper cell layers of the acanthotic epidermis.
While, even though our immunoblotting analysis showed strong expression of CEACAM6 with F106-88 (MoAb specific for CEACAM6), our immunohistochemical analysis showed only a week positive signal (some lesions were even negative) with the same antibody in the epidermal keratinocytes. The reason for this weak staining could be because F106-88 antibody is not suitable for detecting naive protein, in contrast to its high immunoreactivity in immunoblotting.
Infiltrating inflammatory cells showed strong positive signal for not only Dako-PoAb and F34-187 but also F106-88, suggesting that CEACAM6 was strongly expressed in the inflammatory cells.
Immunohistochemical and double immunoenzymatic revealed that the CEACAMs expression correlated with the overexpression of involucrin, PCNA, Ki-67 and CK16. These results suggest that both CEA and CEACAM6 are induced on epidermal keratinocytes in psoriasis lesions, and that the expression may be associated with the state of dedifferentiation of the actively proliferating keratinocytes of the disease. Up-regulated expression of CEA and other CEACAM members only in the upper epidermal cell layers was also demonstrated in keratinocytic neoplasma [7] and verruca vulgarisin in our previous studies [7, 16] , suggesting the differentiation-related expression of these molecules also exists in the proliferatively active keratinocytes in the neoplastic skin conditions. It is currently well known that CEA and CEACAM6 are up-regulated in a wide variety of human cancers, including colon, breast, pancreatic, and lung cancer [17] . Functional analyses have indicated that CEA and CEACAM6 can inhibit differentiation [18] and anoikis [19] of a number of different cell lines. An inverse correlation between the cell surface levels of CEA and CEACAM6 and the degree of differentiation of the tumors has also been shown [20] .
CEACAM1 was reported to be expressed only in outer epidermal cell layers in association with Munro's microabscess [12] . However, in the present study, CEA was expressed diffusely in the upper epidermal cell layers, not only in association with the Munro's microabscess. 
